Fecal Microbiota-based Therapies for Select Gastrointestinal Disease
Key Points
Key Points
- Fecal microbiota-based therapies include conventional fecal microbiota transplant (FMT) and US Food and Drug Administration (FDA)-approved therapies, fecal microbiota live-jslm and fecal microbiota spores live-brpk.
- This guideline provides recommendations on the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection (CDI), severe to fulminant C. difficile infection and inflammatory bowel diseases (IBDs) including pouchitis, ulcerative colitis (UC) and irritable bowel syndrome (IBS).
Treatment
...eatment
...mmendation 1In immunocompetent adults with recurre...
...ng considerations are specific to imm...
...on 2 (part 1)In mildly or moderately immunocomprom...
...ly or moderately immunocompromised a...
...tion 2 (part 2)In severely immunocompr...
...rely immunocompromised includes patie...
...tion 3In adults hospitalized with severe o...
...llowing considerations are specific to adul...
Recommendation 4In adults with ulcerative c...
...ventional FMT can reasonably be used in the con...
...n 5In adults with Crohn’s disease, the...
...The recommendation is specific to the use of c...
...6In adults with pouchitis, the AGA suggests a...
...recommendation is specific to the u...
...ion 7In adults with irritable bowe...
...mmendation is specific to the use of conve...
...Use of Fecal Microbiota-Based Therapies in A...